RxDoctor Payments Data

Hassan Bazzi, DO

Internal Medicine · Troy, MINPI 1457507006

Payments from drug & device makers

$376in general payments, 2019–2025

Across 19 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$89
  • Pfizer$51
  • Cardiva Medical, Inc.$50
  • Boston Scientific$48
  • Sumitomo Pharma America, Inc.$45
  • Teva Pharmaceuticals USA, Inc.$22
  • plus $71 from 4 others

What the payments were for

  • Food & beverage$35695%
  • Education$205%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$376 in reported general payments places this provider in the 60th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$445,654
Medicare patients
803
Services billed
3,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,411$358,937
IngrezzaValbenazine Tosylate32$250,255
SantylCollagenase Clostridium Hist.103$174,739
GemtesaVibegron463$105,096
XareltoRivaroxaban277$56,237
NuplazidPimavanserin Tartrate11$54,020
EntrestoSacubitril/Valsartan200$52,939
TrulicityDulaglutide51$51,520
JardianceEmpagliflozin194$49,441
VraylarCariprazine Hcl45$41,922
Atorvastatin Calcium2,826$34,833
JanuviaSitagliptin Phosphate131$34,023
NuedextaDextromethorphan Hbr/Quinidine33$31,736
Incruse ElliptaUmeclidinium Bromide82$28,572
Breo ElliptaFluticasone/Vilanterol64$27,118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$51$358,9371,411 claims
Sumitomo Pharma America, Inc.Gemtesa$45$105,096463 claims
MerckJanuvia$22$34,023131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →